

# HOUSE BILL No. 5475

September 25, 2009, Introduced by Reps. Simpson, Mayes, Cushingberry, Spade, Sheltroun, Geiss, Womack, Huckleberry and Slavens and referred to the Committee on Health Policy.

A bill to amend 1984 PA 323, entitled  
"The health care false claim act,"  
by amending section 2 (MCL 752.1002) and by adding section 8b.

**THE PEOPLE OF THE STATE OF MICHIGAN ENACT:**

1       Sec. 2. As used in this act:

2       (a) "Claim" means any attempt to cause a health care  
3 corporation or health care insurer to make the payment of a health  
4 care benefit.

5       (b) "Deceptive" means making a claim to a health care  
6 corporation or health care insurer which contains a statement of  
7 fact or which fails to reveal a material fact, which statement or  
8 failure leads the health care corporation or health care insurer to  
9 believe the represented or suggested state of affair to be other

1 than it actually is.

2 (c) "False" means wholly or partially untrue or deceptive.

3 (d) "Health care benefit" means the right under a contract or  
4 a certificate or policy of insurance to have a payment made by a  
5 health care corporation or health care insurer for a specified  
6 health care service.

7 (e) "Health care corporation" means a nonprofit dental care  
8 corporation incorporated under ~~Act No. 125 of the Public Acts of~~  
9 ~~1963, being sections 550.351 to 550.373 of the Michigan Compiled~~  
10 ~~Laws 1963 PA 125, MCL 550.351 TO 550.373~~; a hospital service  
11 corporation, medical care corporation, or a consolidated hospital  
12 service corporation and medical care corporation incorporated or  
13 reincorporated under ~~Act No. 350 of the Public Acts of 1980, being~~  
14 ~~sections 550.1101 to 550.1704 of the Michigan Compiled Laws, or~~  
15 ~~incorporated or consolidated under Act No. 108 or 109 of the Public~~  
16 ~~Acts of 1939~~ **THE NONPROFIT HEALTH CARE CORPORATION REFORM ACT, 1980**  
17 **PA 350, MCL 550.1101 TO 550.1704**; or a health maintenance  
18 organization licensed under ~~Act No. 368 of the Public Acts of 1978,~~  
19 ~~being sections 333.1101 to 333.25211 of the Michigan Compiled Laws~~  
20 **CHAPTER 35 OF THE INSURANCE CODE OF 1956, 1956 PA 218, MCL 500.3501**  
21 **TO 500.3580.**

22 (f) "Health care insurer" means any insurance company  
23 authorized to provide health insurance in this state or any legal  
24 entity which is self-insured and providing health care benefits to  
25 its employees.

26 (g) "Health facility or agency" means a health facility or  
27 agency, as defined in section 20106 of the public health code, ~~Act~~

1 ~~No. 368 of the Public Acts of 1978, being section 333.20106 of the~~  
2 ~~Michigan Compiled Laws 1978 PA 368, MCL 333.20106.~~

3 (h) "Knowing" and "knowingly" means that a person is in  
4 possession of facts under which he or she is aware or should be  
5 aware of the nature of his or her conduct and that his or her  
6 conduct is substantially certain to cause the payment of a health  
7 care benefit. "Knowing" or "knowingly" does not include conduct  
8 which is an error or mistake unless the person's course of conduct  
9 indicates a systematic or persistent tendency to cause inaccuracies  
10 to be present.

11 (i) "Person" means an individual, corporation, partnership,  
12 association, or any other legal entity.

13 (J) "PHARMACY BENEFIT MANAGER" OR "PBM" MEANS A PERSON,  
14 BUSINESS, OR ENTITY THAT PERFORMS PHARMACY BENEFITS MANAGEMENT.  
15 PHARMACY BENEFIT MANAGER OR PBM INCLUDES A PERSON OR ENTITY ACTING  
16 FOR A PBM IN A CONTRACTUAL OR EMPLOYMENT RELATIONSHIP IN THE  
17 PERFORMANCE OF PHARMACY BENEFITS MANAGEMENT FOR A MANAGED CARE  
18 COMPANY, MEDICAL SERVICE ORGANIZATION, INSURANCE COMPANY, THIRD-  
19 PARTY PAYOR, OR A HEALTH PROGRAM ADMINISTERED BY A STATE DEPARTMENT  
20 AND INCLUDES ANY PERSON, CORPORATION, BUSINESS, COMPANY,  
21 ASSOCIATION, UNION, HEALTH CARE GROUP, NETWORK, COLLECTIVE  
22 BARGAINING GROUP, OR ANY OTHER ENTITY THAT PROVIDES PRESCRIPTION  
23 DRUGS OR MEDICAL SUPPLIES, OR BOTH.

24 (K) "PHARMACY BENEFITS MANAGEMENT" MEANS THE ADMINISTRATIVE  
25 PROCEDURES INVOLVED IN THE DELIVERY OF THE PRESCRIPTION DRUG  
26 BENEFIT, INCLUDING, BUT NOT LIMITED TO, CONSTRUCTION AND MANAGEMENT  
27 OF FORMULARIES, NEGOTIATION WITH AND MANAGEMENT OF PROVIDER

1 NETWORKS, DETERMINATION OF CONSUMER COST-SHARING REQUIREMENTS,  
2 COMMUNICATION OF BENEFIT STATUS TO CONSUMERS, CLAIMS PROCESSING,  
3 AND NEGOTIATED REBATES AND DISCOUNTS.

4 SEC. 8B. (1) THE PBM OR ENTITY CONDUCTING AN AUDIT SHALL  
5 FOLLOW THESE PROCEDURES:

6 (A) THE PHARMACY CONTRACT MUST IDENTIFY AND DESCRIBE IN DETAIL  
7 THE AUDIT PROCEDURES.

8 (B) THE PBM OR ENTITY CONDUCTING THE AUDIT SHALL PROVIDE THE  
9 PHARMACY WITH WRITTEN NOTICE AT LEAST 2 WEEKS BEFORE CONDUCTING THE  
10 INITIAL ON-SITE OR OFF-SITE AUDIT FOR EACH AUDIT CYCLE.

11 (C) THE PBM OR ENTITY CONDUCTING THE ON-SITE AUDIT SHALL NOT  
12 INTERFERE WITH THE DELIVERY OF PHARMACIST SERVICES TO A PATIENT AND  
13 SHALL UTILIZE EVERY EFFORT TO MINIMIZE INCONVENIENCE AND DISRUPTION  
14 TO PHARMACY OPERATIONS DURING THE AUDIT PROCESS. AN ENTITY SHALL  
15 NOT CONDUCT AN ON-SITE AUDIT AT A PARTICULAR PHARMACY MORE THAN 1  
16 TIME ANNUALLY. THIS SUBDIVISION DOES NOT APPLY WHEN AN ENTITY MUST  
17 RETURN TO A PHARMACY TO COMPLETE AN AUDIT ALREADY IN PROGRESS,  
18 THERE IS A DOCUMENTED PATTERN OF PAYMENT ERROR SUSTAINED BY THAT  
19 SPECIFIC PHARMACY THROUGHOUT THE AUDITED PERIOD, OR THERE IS  
20 INAPPROPRIATE OR ILLEGAL ACTIVITY THAT THE ENTITY HAS BROUGHT TO  
21 THE ATTENTION OF THE PHARMACY OWNER OR CORPORATE HEADQUARTERS OF  
22 THE PHARMACY.

23 (D) ANY AUDIT THAT INVOLVES CLINICAL OR PROFESSIONAL JUDGMENT  
24 MUST BE CONDUCTED BY OR IN CONSULTATION WITH A PHARMACIST LICENSED  
25 IN THIS STATE.

26 (E) ANY CLERICAL OR RECORD-KEEPING ERROR, SUCH AS A  
27 TYPOGRAPHICAL ERROR, SCRIVENER'S ERROR, OR COMPUTER ERROR,

1 REGARDS A REQUIRED DOCUMENT OR RECORD SHALL NOT ON ITS FACE  
2 CONSTITUTE FRAUD, BUT MAY BE SUBJECT TO RECOUPMENT. A CLAIM UNDER  
3 THIS SUBDIVISION IS NOT SUBJECT TO CRIMINAL PENALTIES WITHOUT PROOF  
4 OF INTENT TO COMMIT FRAUD.

5 (F) A PHARMACY MAY USE ELECTRONIC RECORDS, INCLUDING  
6 ELECTRONIC BENEFICIARY SIGNATURE LOGS, ELECTRONIC TRACKING OF  
7 PRESCRIPTIONS, ELECTRONIC PRESCRIBER PRESCRIPTION TRANSMISSIONS AND  
8 IMAGERY OF HARD COPY PRESCRIPTIONS, AND ANY OTHER REASONABLY CLEAR  
9 AND ACCURATE ELECTRONIC DOCUMENTATION, AND THESE RECORDS ARE  
10 ACCEPTABLE FOR AUDITING UNDER THE SAME TERMS AND CONDITIONS AND FOR  
11 THE SAME PURPOSES AS THEIR PAPER ANALOGS. IF PAPER LOGS ARE USED,  
12 AUDITORS MUST LOOK AT LEAST 14 DAYS PAST THE DISPENSE DATE TO CHECK  
13 FOR PATIENT PICKUP. POINT OF SALE ELECTRONIC REGISTER DATA SHALL  
14 QUALIFY AS PROOF OF DELIVERY TO THE PATIENT.

15 (G) A FINDING OF AN OVERPAYMENT OR UNDERPAYMENT MUST BE BASED  
16 ON THE ACTUAL OVERPAYMENT OR UNDERPAYMENT AND MAY NOT BE A  
17 PROJECTION BASED ON THE NUMBER OF PATIENTS SERVED HAVING A SIMILAR  
18 DIAGNOSIS OR ON THE NUMBER OF SIMILAR ORDERS OR REFILLS FOR SIMILAR  
19 DRUGS. RECOUPMENT OF CLAIMS MUST BE BASED ON THE ACTUAL OVERPAYMENT  
20 OR UNDERPAYMENT UNLESS THE PHARMACY AGREES OTHERWISE AS PART OF A  
21 SETTLEMENT.

22 (H) RECOUPMENT OR PAYMENT ADJUSTMENTS OF CLAIMS MUST BE BASED  
23 ON THE ACTUAL OVERPAYMENT OR UNDERPAYMENT UNLESS THE PHARMACY  
24 AGREES TO A PROJECTION AS PART OF A SETTLEMENT.

25 (I) A FINDING OF AN UNDERPAYMENT SHALL BE REIMBURSED WITH  
26 INTEREST FOR THE TIME PERIOD BETWEEN DETECTION AND PAYMENT.

27 (J) EACH PHARMACY SHALL BE AUDITED UNDER THE SAME SAMPLING

1 STANDARDS, PARAMETERS, AND PROCEDURES AS OTHER SIMILARLY LICENSED  
2 PHARMACIES AUDITED BY THE PBM OR ENTITY CONDUCTING THE AUDIT. THE  
3 PHARMACY SHALL BE PROVIDED SAMPLES OF THE STANDARD PARAMETERS AND  
4 PROCEDURES FOR THE AUDITS BEING CONDUCTED.

5 (K) THE PERIOD COVERED BY AN AUDIT MAY NOT EXCEED 1 YEAR FROM  
6 THE DATE THE CLAIM WAS SUBMITTED TO OR ADJUDICATED BY A MANAGED  
7 CARE COMPANY, MEDICAL SERVICE ORGANIZATION, INSURANCE COMPANY,  
8 THIRD-PARTY PAYOR, OR HEALTH PROGRAM ADMINISTERED BY A STATE  
9 DEPARTMENT.

10 (L) AN ON-SITE AUDIT MAY NOT BE INITIATED OR SCHEDULED DURING  
11 THE FIRST 7 CALENDAR DAYS OF ANY MONTH DUE TO THE HIGH VOLUME OF  
12 PRESCRIPTIONS FILLED IN THE PHARMACY DURING THAT TIME UNLESS  
13 OTHERWISE CONSENTED TO BY THE PHARMACIST. THE PBM IS RESPONSIBLE  
14 FOR CONFIRMING RECEIPT OF THE AUDIT NOTICE BY THE PHARMACY. THE  
15 PHARMACY RESERVES THE RIGHT TO REFUSE TO COMPLY WITH ANY AUDIT FOR  
16 WHICH THE PBM DID NOT CONFIRM, AND THE PBM IS PROHIBITED FROM  
17 TAKING ANY ADVERSE ACTION AGAINST THE PHARMACY DUE TO THE REFUSAL  
18 BY THE PHARMACY UNDER THIS SUBDIVISION.

19 (M) THE PBM OR ENTITY CONDUCTING AN AUDIT MAY NOT RECEIVE  
20 PAYMENT BASED ON A PERCENTAGE OF THE AMOUNT RECOVERED. THE PBM OR  
21 ENTITY CONDUCTING THE AUDIT SHALL DISCLOSE TO THE PLAN SPONSOR ANY  
22 MONEY RECOUPED IN THE AUDIT.

23 (N) IF THE DISCREPANCY EXCEEDS \$25,000.00 IN OVERPAYMENT,  
24 FUTURE PAYMENTS TO THE PHARMACY MAY BE WITHHELD AFTER FINALIZATION  
25 OF THE AUDIT.

26 (O) UNDERPAYMENTS SHALL BE RESTORED IN THE NEXT PAYMENT CYCLE  
27 UPON COMPLETION OF THE AUDIT.

1 (P) A FINDING OF AN OVERPAYMENT SHALL NOT INCLUDE THE  
2 DISPENSING FEE AMOUNT.

3 (2) THE PBM OR ENTITY CONDUCTING THE AUDIT MUST PROVIDE THE  
4 PHARMACY WITH A WRITTEN REPORT OF THE AUDIT AND COMPLY WITH ALL OF  
5 THE FOLLOWING REQUIREMENTS:

6 (A) THE PRELIMINARY AUDIT REPORT MUST BE DELIVERED TO THE  
7 PHARMACY NOT MORE THAN 90 DAYS AFTER CONCLUSION OF THE AUDIT.

8 (B) THE PHARMACY SHALL BE ALLOWED NOT LESS THAN 60 DAYS  
9 FOLLOWING RECEIPT OF THE PRELIMINARY AUDIT REPORT IN WHICH TO  
10 PRODUCE DOCUMENTATION TO ADDRESS ANY DISCREPANCY FOUND DURING THE  
11 AUDIT.

12 (C) A FINAL AUDIT REPORT SHALL BE DELIVERED TO THE PHARMACY  
13 NOT MORE THAN 120 DAYS AFTER RECEIPT OF THE PRELIMINARY AUDIT  
14 REPORT OR FINAL APPEAL WITH THE OFFICE OF FINANCIAL AND INSURANCE  
15 REGULATION.

16 (D) THE AUDIT REPORT MUST BE SIGNED AND INCLUDE THE SIGNATURE  
17 OF ANY PHARMACIST PARTICIPATING IN THE AUDIT.

18 (E) ANY RECOUPMENTS OF DISPUTED FUNDS AND RESTORATION OF  
19 OVERPAYMENT SHALL ONLY OCCUR AFTER FINAL INTERNAL DISPOSITION OF  
20 THE AUDIT, INCLUDING THE APPEALS PROCESS AS SET FORTH IN SUBSECTION  
21 (3).

22 (F) INTEREST SHALL NOT ACCRUE DURING THE AUDIT PERIOD.

23 (G) EACH PBM OR ENTITY CONDUCTING AN AUDIT SHALL PROVIDE A  
24 COPY OF THE FINAL AUDIT REPORT, AFTER COMPLETION OF ANY REVIEW  
25 PROCESS, TO THE PLAN SPONSOR.

26 (3) THE NATIONAL COUNCIL FOR PRESCRIPTION DRUG PROGRAMS OR ANY  
27 OTHER RECOGNIZED NATIONAL INDUSTRY STANDARD SHALL BE USED TO

1 EVALUATE CLAIMS SUBMISSION AND PRODUCT SIZE DISPUTES. AN APPEALS  
2 PROCESS WILL BE CONDUCTED BY THE OFFICE OF FINANCIAL AND INSURANCE  
3 REGULATION BEFORE A NEUTRAL PARTY. IF, FOLLOWING THE APPEAL, THE  
4 PBM OR ENTITY CONDUCTING AN AUDIT FINDS THAT AN UNFAVORABLE AUDIT  
5 REPORT OR ANY PORTION OF THAT REPORT IS UNSUBSTANTIATED, THE PBM OR  
6 ENTITY CONDUCTING THE AUDIT SHALL DISMISS THE AUDIT REPORT OR  
7 PORTION IN QUESTION WITHOUT THE NECESSITY OF ANY FURTHER ACTION.

8 (4) NOTWITHSTANDING ANY OTHER PROVISION OF THIS ACT, THE PBM  
9 OR ENTITY CONDUCTING THE AUDIT SHALL NOT USE THE ACCOUNTING  
10 PRACTICE OF EXTRAPOLATION IN CALCULATING RECOUPMENTS, RESTORATION,  
11 OR PENALTIES FOR AUDITS. AN EXTRAPOLATION AUDIT MEANS AN AUDIT OF A  
12 SAMPLE OF PRESCRIPTION DRUG BENEFIT CLAIMS SUBMITTED BY A PHARMACY  
13 TO THE PBM OR ENTITY CONDUCTING THE AUDIT THAT IS THEN USED TO  
14 ESTIMATE AUDIT RESULTS FOR A LARGER BATCH OR GROUP OF CLAIMS NOT  
15 REVIEWED BY THE AUDITOR. AUDIT CONCLUSIONS SHALL BE BASED ON  
16 SEVERAL OF THE FOLLOWING STATISTICAL CONSIDERATIONS:

17 (A) THE AUDIT SAMPLE SHALL CONSIST OF RANDOMLY SELECTED  
18 PRESCRIPTIONS WITH DATES OF SERVICE INCLUDED WITHIN THE STATED  
19 AUDIT PERIOD. THE PBM SHALL REIMBURSE THE PHARMACY FOR ALL TIME AND  
20 EXPENSES INCURRED IN PROVIDING DOCUMENTS FOR THE AUDIT.

21 (B) CLAIMS IN THE SAMPLE, FOR WHICH A PHARMACY WAS UNDERPAID,  
22 ARE CONSIDERED AS WELL AS ANY CLAIMS IN THE SAMPLE INVOLVING  
23 OVERPAYMENTS.

24 (C) THE AUDIT SAMPLE SHALL REFLECT THE COMPOSITION OF THE  
25 PHARMACY'S CLAIMS, INCLUDING, BUT NOT LIMITED TO, A RANDOM SAMPLE  
26 THAT INCLUDES THE SAME RATIO OF BRAND NAME TO GENERIC PRESCRIPTIONS  
27 OR PROPORTION OF COMPOUNDING, SPECIALTY, HIGH-COST MEDICATIONS, OR



1 OTHER UNIQUE CHARACTERISTICS OF THE PROFILE OF PRESCRIPTIONS  
2 DISPENSED.

3 (D) THE SAMPLE SHALL NOT INCLUDE SOLELY HIGH-PRICED  
4 MEDICATIONS OR A PREPONDERANCE OF THE SAME DRUG ITEM.

5 (E) THE SAMPLE SIZE SHALL BE APPROPRIATE AND CONSISTENT WITH  
6 ESTABLISHED SCIENTIFIC PRINCIPLES ASSURING PROTECTION AGAINST  
7 SELECTION BIAS.

8 (F) THE STANDARD DEVIATION OR THE STANDARD ERROR EMPLOYED BY  
9 THE SPECIFIC AUDITING METHODOLOGY SHALL BE DEFINED AND CONSISTENT  
10 WITH COMMONLY ACCEPTED SCIENTIFIC PRINCIPLES.

11 (G) IN THE EVENT OF AN IMPASSE OCCURRING OVER METHODOLOGY,  
12 SAMPLE SIZE, OR RANDOMNESS THAT ACCOMPANIES AN AUDIT CONCLUSION,  
13 THE DECISION OF THE OFFICE OF FINANCIAL AND INSURANCE REGULATION IN  
14 CONSULTATION WITH A QUALIFIED STATISTICIAN WILL BE FINAL.

15 (5) THE AUDIT CRITERIA SET FORTH IN THIS SECTION APPLIES ONLY  
16 TO AUDITS OF CLAIMS FOR SERVICES PROVIDED AND CLAIMS SUBMITTED FOR  
17 PAYMENT AFTER JANUARY 1, 2010. THIS SECTION DOES NOT APPLY TO ANY  
18 INVESTIGATIVE AUDIT CONDUCTED BY OR ON BEHALF OF A STATE AGENCY  
19 THAT INVOLVES FRAUD, WILLFUL MISREPRESENTATION, OR ABUSE, INCLUDING  
20 WITHOUT LIMITATION INVESTIGATIVE AUDITS OR ANY OTHER STATUTORY  
21 PROVISION THAT AUTHORIZES INVESTIGATION RELATING TO INSURANCE  
22 FRAUD.